Augusto Pessina, Beatriz Albella, Maria Bayo, Juan Bueren, Paul Brantom, Silvia Casati, Cristina Croera, Ralph Parchment, Dominique Parent-Massin, Greet Schoeters, Yann Sibiri, Rosette Van Den Heuvel and Laura Gribaldo
In a prevalidation study, a Standard Operating Procedure (SOP) for human and mouse in vitro tests was developed, for evaluating the potential haematotoxicity of xenobiotics in terms of their direct, adverse effects on the myeloid colony-forming unit (CFU-GM). Based on the adjustment of the mousederived maximum tolerated dose (MTD), a prediction model was set up to calculate the human MTD, and an international blind trial was designed to apply this model to the clinical neutropenia of 23 drugs including 17 antineoplastics. The model correctly predicted the human MTD for 20 drugs out of the 23 (87%). This high percentage of predictivity, and the reproducibility of the SOP testing, confirmed the scientific validation of this model, and suggested promising applications for developing and validating other in vitro methods for use in haematotoxicology.
You need to register (for free) to download this article. Please log in/register here.